Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:14679122rdf:typepubmed:Citationlld:pubmed
pubmed-article:14679122lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:14679122lifeskim:mentionsumls-concept:C0014852lld:lifeskim
pubmed-article:14679122lifeskim:mentionsumls-concept:C0699791lld:lifeskim
pubmed-article:14679122lifeskim:mentionsumls-concept:C2347678lld:lifeskim
pubmed-article:14679122lifeskim:mentionsumls-concept:C0123931lld:lifeskim
pubmed-article:14679122lifeskim:mentionsumls-concept:C0282460lld:lifeskim
pubmed-article:14679122lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:14679122pubmed:issue1lld:pubmed
pubmed-article:14679122pubmed:dateCreated2003-12-17lld:pubmed
pubmed-article:14679122pubmed:abstractTextThe purpose of this study was to assess the efficacy and toxicity of irinotecan and 5-fluorouracil (5-FU) in primary refractory or relapsed locally advanced or metastatic oesophagogastric (O-G) carcinoma.lld:pubmed
pubmed-article:14679122pubmed:languageenglld:pubmed
pubmed-article:14679122pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14679122pubmed:citationSubsetIMlld:pubmed
pubmed-article:14679122pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14679122pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14679122pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14679122pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14679122pubmed:statusMEDLINElld:pubmed
pubmed-article:14679122pubmed:monthJanlld:pubmed
pubmed-article:14679122pubmed:issn0923-7534lld:pubmed
pubmed-article:14679122pubmed:authorpubmed-author:BrownGGlld:pubmed
pubmed-article:14679122pubmed:authorpubmed-author:WardCClld:pubmed
pubmed-article:14679122pubmed:authorpubmed-author:CunninghamDDlld:pubmed
pubmed-article:14679122pubmed:authorpubmed-author:HillM EMElld:pubmed
pubmed-article:14679122pubmed:authorpubmed-author:OatesJJlld:pubmed
pubmed-article:14679122pubmed:authorpubmed-author:WatersJ SJSlld:pubmed
pubmed-article:14679122pubmed:authorpubmed-author:NormanA RARlld:pubmed
pubmed-article:14679122pubmed:authorpubmed-author:AssersohnLLlld:pubmed
pubmed-article:14679122pubmed:issnTypePrintlld:pubmed
pubmed-article:14679122pubmed:volume15lld:pubmed
pubmed-article:14679122pubmed:ownerNLMlld:pubmed
pubmed-article:14679122pubmed:authorsCompleteYlld:pubmed
pubmed-article:14679122pubmed:pagination64-9lld:pubmed
pubmed-article:14679122pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:14679122pubmed:meshHeadingpubmed-meshheading:14679122...lld:pubmed
pubmed-article:14679122pubmed:meshHeadingpubmed-meshheading:14679122...lld:pubmed
pubmed-article:14679122pubmed:meshHeadingpubmed-meshheading:14679122...lld:pubmed
pubmed-article:14679122pubmed:meshHeadingpubmed-meshheading:14679122...lld:pubmed
pubmed-article:14679122pubmed:meshHeadingpubmed-meshheading:14679122...lld:pubmed
pubmed-article:14679122pubmed:meshHeadingpubmed-meshheading:14679122...lld:pubmed
pubmed-article:14679122pubmed:meshHeadingpubmed-meshheading:14679122...lld:pubmed
pubmed-article:14679122pubmed:meshHeadingpubmed-meshheading:14679122...lld:pubmed
pubmed-article:14679122pubmed:meshHeadingpubmed-meshheading:14679122...lld:pubmed
pubmed-article:14679122pubmed:meshHeadingpubmed-meshheading:14679122...lld:pubmed
pubmed-article:14679122pubmed:meshHeadingpubmed-meshheading:14679122...lld:pubmed
pubmed-article:14679122pubmed:meshHeadingpubmed-meshheading:14679122...lld:pubmed
pubmed-article:14679122pubmed:meshHeadingpubmed-meshheading:14679122...lld:pubmed
pubmed-article:14679122pubmed:meshHeadingpubmed-meshheading:14679122...lld:pubmed
pubmed-article:14679122pubmed:meshHeadingpubmed-meshheading:14679122...lld:pubmed
pubmed-article:14679122pubmed:meshHeadingpubmed-meshheading:14679122...lld:pubmed
pubmed-article:14679122pubmed:meshHeadingpubmed-meshheading:14679122...lld:pubmed
pubmed-article:14679122pubmed:year2004lld:pubmed
pubmed-article:14679122pubmed:articleTitlePhase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.lld:pubmed
pubmed-article:14679122pubmed:affiliationRoyal Marsden Hospital, London and Sutton, Surrey, UK.lld:pubmed
pubmed-article:14679122pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:14679122pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:14679122pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:14679122pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:14679122pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14679122lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14679122lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14679122lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14679122lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14679122lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14679122lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14679122lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14679122lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14679122lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14679122lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14679122lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14679122lld:pubmed